SNDX: Strong commercial growth and pivotal clinical catalysts set the stage for major pipeline advances
Two commercial assets are driving strong revenue growth, with real-world data supporting expanded use and maintenance therapy as a key growth driver. Multiple near-term clinical readouts, including for IPF and cGVHD, and a robust pipeline position the company for significant advancement.Based on Sy…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.